Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
15 results
  • Drug Class Review: Fixed Dose Combination Drug Products for the Treatment of Type 2 Diabetes and Hyperlipidemia: Final Report [BOOK]
    Drug Class Review: Fixed Dose Combination Drug Products for the Treatment of Type 2 Diabetes and Hyperlipidemia: Final Report. Oregon Health & Science University: Portland (OR)McDonagh M, Peterson K, … Dana TBOOK
  • The combination of 2 drug entities in one dosage form is known as a fixed-dose combination product (FDCP). For the treatment of type 2 diabetes, there are 2 products that combine a sulfonylurea with metformin, 2 that combine metformin with a thiazolidinedione, 1 that combines metformin with a Dipeptidyl-Peptidase 4 (DPP-4) Inhibitor, and 2 that combine a thiazolidinedione with a sulfonylurea. For…
  • Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. [Journal Article]
    Prev Cardiol. 2005 Fall; 8(4):226-33.Bays HE, McGovern ME
  • Time may be an important variable when evaluating the efficacy of lipid-altering drugs. In this analysis of the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation, niacin extended-release/lovastatin 1000/40 mg was as effective as atorvastatin 10 mg and more effective than simvastatin (both 10 mg and 20 mg) in achieving low-density lipoprotein cholesterol and non-high-density lipo…
  • Extended-release niacin/lovastatin: the first combination product for dyslipidemia. [Review]
    Expert Rev Cardiovasc Ther. 2004 Jul; 2(4):485-501.Bays HE
  • Many clinical studies have demonstrated that lipid-altering drug treatments, including the use of statin and niacin monotherapy, can be effective in the primary and secondary prevention of coronary heart disease, but only in a minority of patients relative to placebo. Since statins and niacin have entirely different mechanisms of action and predominantly different effects on blood lipid levels, t…
  • The development of combination drugs for atherosclerosis. [Review]
    Curr Atheroscler Rep. 2003 Jan; 5(1):29-32.Black DM
  • The complexity of medical care has led to a dramatic increase in the number of drugs taken by patients. In an effort to improve patient compliance and the effectiveness of clinical care, many drugs are being studied for combination in a single capsule or tablet. The recent success of many combination drugs for hypertension has accelerated the interest in combination drugs for lipids and atheroscl…
  • Niacin extended-release/lovastatin: combination therapy for lipid disorders. [Review]
    Expert Opin Pharmacother. 2002 Dec; 3(12):1763-71.Moon YS, Kashyap ML
  • The new combination of niacin extended-release (ER) and lovastatin (Advicor, Kos pharmaceuticals), is a powerful lipid modifying agent and takes advantage of the different mechanisms of action of its two components. Niacin decreases hepatic atherogenic apolipoprotein (apo) B production whereas lovastatin increases apoB removal. Whereas niacin potently increases high density lipoprotein (HDL) leve…
New Search